Replies to post #35468 on Revive Therapeutics Ltd (RVVTF)

[Giovanni]

This Vitamin Supplement Linked To 40% Lower Dementia Risk

{take a guess}

It is thought that the vitamin helps clear the brain of the characteristic tangles of proteins that form in dementia.

Taking vitamin D supplement could decrease dementia risk, a large study suggests.

People who took vitamin D supplements lived for longer without developing dementia and overall had a 40 percent lower risk of developing the disease.

Adequate vitamin D levels have been repeatedly linked to lower dementia risk by research ( 1, 2, 3, 4).

One study has even suggested that adequate levels of vitamin D could prevent almost one-in-five cases of dementia ( Navale et al., 2022).

However, the link remains somewhat controversial, with other studies finding no connection (also: Owusu et al., 2018).

Professor Zahinoor Ismail, the study’s first author, acknowledged the contradictory findings from past studies:

“We know that vitamin D has some effects in the brain that could have implications for reducing dementia, however so far, research has yielded conflicting results.

Our findings give key insights into groups who might be specifically targeted for vitamin D supplementation.

Overall, we found evidence to suggest that earlier supplementation might be particularly beneficial, before the onset of cognitive decline.”

Vitamin D and dementiaFor this study, data from over 12,000 participants in the US National Alzheimer’s Coordinating Center was analysed.

Just over one-third were taking vitamin D supplements.

The results showed that vitamin D supplementation was associated with a reduced dementia risk in all groups.

However, the connection was stronger in women and people who had no pre-existing cognitive deficits, such as mild cognitive impairment.

Similarly, carriers of the APOEe4 gene appeared to benefit more from vitamin D supplementation.

The APOEe4 gene significantly increases the risk of developing dementia.

It is thought that vitamin D helps to clear the brain of the characteristic tangles of proteins that form, known as amyloid and tau.

Dr Byron Creese, study co-author, said:

“Preventing dementia or even delaying its onset is vitally important given the growing numbers of people affected.

The link with vitamin D in this study suggests that taking vitamin D supplements may be beneficial in preventing or delaying dementia, but we now need clinical trials to confirm whether this is really the case.

The ongoing VitaMIN D study at the University of Exeter is exploring this issue further by randomly assigning participants to either take vitamin D or placebo and examining changes in memory and thinking tests over time.”

[Giovanni]

Single-Dose Psilocybin Promising for Resistant Depression
Liam Davenport

April 06, 2023
11
162
Share
Add to Email Alerts
PARIS — A single 25-mg dose of a synthetic formulation of psilocybin appears to improve the core symptoms of treatment-resistant depression (TRD), a new analysis of phase 2 trial data suggests.

Known as COMP360, the synthetic agent, a proprietary, purified form of psilocybin, improved symptoms related to mood and anhedonia while leaving aspects such as appetite and weight changes unaffected, report investigators led by Guy Goodwin, PhD, emeritus professor of psychiatry, University of Oxford, UK, and chief medical officer, COMPASS Pathways.

The study was presented here at the European Psychiatric Association (EPA) 2023 Congress.

100 Million Affected
Affecting up to 100 million people globally, TRD is "not an official diagnosis," although it is often defined as the failure to elicit a response with at least two antidepressant treatments, said Goodwin.

Compared to their counterparts with non-TRD, those with TRD experience higher relapse rates, higher rates of suicidal behavior, and more residual symptoms even when they do respond to treatment.

Previous results from the study known as P-TRD indicated that a single 25-mg dose of COMP360 significantly reduced depression scores for up to 12 weeks when given along with psychological support, although a later analysis suggested the effect subsequently dropped off.

The vast majority of the patients in the trial were naive to psychedelics, and so, Goodwin explained, they undergo a preparation phase during which they receive psychoeducation and have at least two visits with a therapist, who then stays with them during administration of the drug to offer support if they experience psychological distress.

Following the psilocybin session, participants go through a process known as integration, which involves two sessions with a therapist within 2 weeks.